Generalidades de resistencia bacteriana en terapia intensiva
Palabras clave:
Infecciones Nosocomiales, Resistencia Bacteriana, GérmenesResumen
Las infecciones nosocomiales debidas a gérmenes multirresistentes (entre las cuales las neumonías ocupan un lugar preponderante) se encuentran entre las infecciones emergentes y como tales constituyen uno de los problemas de salud más importantes a resolver en los próximos años. Múltiples evidencias demuestran que la resistencia bacteriana en las UTI tiene un impacto sustantivo en el pronóstico de los pacientes Los gérmenes presentes en pacientes internados en las UTI pueden provenir del medio ambiente, de la flora corporal normal o adquirirse por contacto con otros pacientes o trabajadores de la salud.Descargas
Los datos de descargas todavía no están disponibles.
Citas
1. Austrian R, Gold J. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med 1964;60:759-776.
2. Ban N, Nissen P, Hansen J, Moore PB, Steitz TA. The complete atomic structure of the large ribosomal subunit at 2.4 A resolution. Science 2000;289:905-920.
3. Barnett ED, Klein JO. The problem of resistant bacteria for the management of acute otitis media. Pediatr Clin North Am 1995;42:509-517.
4. Bartlett JG, Breiman RF, Mandell LA, File TM. Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis 1998;26:811-838.
5. Bisno AL. Acute pharyngitis. N Engl J Med 2001;344:205-211.[Full Text]
6. Black S, Shinefield H, Fireman B. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000;19:187-195.
7. Breiman RF, Butler JC, Tenover FC, Elliott JA, Facklam RR. Emergence of drug-resistant pneumococcal infections in the United States. JAMA 1994;271:1831-1835.
8. Buckingham SC, Brown SP, Joaquin VH. Breakthrough bacteremia and meningitis during treatment with cephalosporins parenterally for pneumococcal pneumonia. J Pediatr 1998;132:174-176.
9. Catalan MJ, Fernandez JM, Vazquez A, Varela de Seijas E, Suarez A, Bernaldo de Quiros JC. Failure of cefotaxime in the treatment of meningitis due to relatively resistant Streptococcus pneumoniae. Clin Infect Dis 1994;18:766-769.
10. Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999;341:233-239.
11. Chen FM, Breiman RF, Farley M, Plikaytis B, Deaver K, Cetron MS. Geocoding and linking data from population-based surveillance and the US Census to evaluate the impact of median household income on the epidemiology of invasive Streptococcus pneumoniae infections. Am J Epidemiol 1998;148:1212-1218.
12. Choi E, Lee HJ. Clinical outcome of invasive infections by penicillin-resistant Streptococcus pneumoniae in Korean children. Clin Infect Dis 1998;26:1346-1354.
13. Dagan R, Abramson O, Leibovitz E. Bacteriologic response to oral cephalosporins: are established susceptibility breakpoints appropriate in the case of acute otitis media? J Infect Dis 1997;176:1253-1259.
14. Dagan R, Melamed R, Muallem M. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis 1996;174:1271-1278.
15. Dagan R, Muallem M, Melamed R, Leroy O, Yagupsky P.
Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid. Pediatr Infect Dis J 1997;16:1060-1064.
16. Dean AG, Dean JA, Coulombier D. Epi Info, version 6: a word processing, database, and statistics program for public health on IBM-compatible microcomputers. Atlanta: Centers for Disease Control and Prevention, 1995.
17. Deeke SL, Palacio R, Ruvinsky R, et al. Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae. Pediatrics 1999;103:409-413.
18. del Castillo F, Baquero-Artigao F, Garcia-Perea A. Influence of recent antibiotic therapy on antimicrobial resistance of Streptococcus pneumoniae in children with acute otitis media in Spain. Pediatr Infect Dis J 1998;17:94-97.
19. Depardieu F, Courvalin P. Mutation in 23S RNA responsible for resistance to 16-membered macrolides and streptogramins in Streptococcus pneumoniae. Antimicrob Agents Chemother 2001;45:319-323.
20. Doern GV, Brueggemann AB, Huynh H, Wingert E. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997 98. Emerg Infect Dis 1999;5:757-765.
21. Dowell SF, Butler JC, Giebink GS. Acute otitis media: management and surveillance in an era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J 1999;18:1-9.
22. Dowell SF, Smith T, Leversedge K, Snitzer J. Failure of pneumonia treatment associated with highly resistant pneumococci in a child. Clin Infect Dis 1999;29:462-463.
23. Dunne WM Jr, Kehl KS, Holland-Staley CA, Brueggemann AB, Pfaller MA, Doern GV. Comparison of results generated by serotyping, pulsed-field restriction analysis, ribotyping, and repetitive-sequence PCR used to characterize penicillin-resistant pneumococci from the United States. J Clin Microbiol 2001;39:1791-1795.
24. Feikin DR, Schuchat A, Kolczak M. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000;90:223-229.
25. Heffelfinger JD, Dowell SF, Jorgensen JH. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000;160:1399-1408.
26. Hofmann J, Cetron MS, Farley MM, et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995;333:481-486.
27. Jacobs MR. Increasing importance of antibiotic-resistant Streptococcus pneumoniae in acute otitis media. Pediatr Infect Dis J 1996;15:940-943.
28. Tait-Kamradt A, Davies T, Appelbaum PC. Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob Agents Chemother 2000;44:3395-3401.
29. Thornsberry C, Ogilvie PT, Holley HP, Sahm DF. In vitro activity of grepafloxacin and 25 other antimicrobial agents against Streptococcus pneumoniae: correlation with penicillin resistance. Clin Ther 1998;20:1179-1190.
30. Turett GS, Blum S, Fazal BA, Justman JE, Telzak EE. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. Clin Infect Dis 1999;29:321-327.
31. Unge J, Berg A, Al-Kharadaghi S. The crystal structure of ribosomal protein L22 from Thermus thermophilus: insights into the mechanism of erythromycin resistance. Structure 1998;6:1577-1586.
2. Ban N, Nissen P, Hansen J, Moore PB, Steitz TA. The complete atomic structure of the large ribosomal subunit at 2.4 A resolution. Science 2000;289:905-920.
3. Barnett ED, Klein JO. The problem of resistant bacteria for the management of acute otitis media. Pediatr Clin North Am 1995;42:509-517.
4. Bartlett JG, Breiman RF, Mandell LA, File TM. Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis 1998;26:811-838.
5. Bisno AL. Acute pharyngitis. N Engl J Med 2001;344:205-211.[Full Text]
6. Black S, Shinefield H, Fireman B. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000;19:187-195.
7. Breiman RF, Butler JC, Tenover FC, Elliott JA, Facklam RR. Emergence of drug-resistant pneumococcal infections in the United States. JAMA 1994;271:1831-1835.
8. Buckingham SC, Brown SP, Joaquin VH. Breakthrough bacteremia and meningitis during treatment with cephalosporins parenterally for pneumococcal pneumonia. J Pediatr 1998;132:174-176.
9. Catalan MJ, Fernandez JM, Vazquez A, Varela de Seijas E, Suarez A, Bernaldo de Quiros JC. Failure of cefotaxime in the treatment of meningitis due to relatively resistant Streptococcus pneumoniae. Clin Infect Dis 1994;18:766-769.
10. Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999;341:233-239.
11. Chen FM, Breiman RF, Farley M, Plikaytis B, Deaver K, Cetron MS. Geocoding and linking data from population-based surveillance and the US Census to evaluate the impact of median household income on the epidemiology of invasive Streptococcus pneumoniae infections. Am J Epidemiol 1998;148:1212-1218.
12. Choi E, Lee HJ. Clinical outcome of invasive infections by penicillin-resistant Streptococcus pneumoniae in Korean children. Clin Infect Dis 1998;26:1346-1354.
13. Dagan R, Abramson O, Leibovitz E. Bacteriologic response to oral cephalosporins: are established susceptibility breakpoints appropriate in the case of acute otitis media? J Infect Dis 1997;176:1253-1259.
14. Dagan R, Melamed R, Muallem M. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis 1996;174:1271-1278.
15. Dagan R, Muallem M, Melamed R, Leroy O, Yagupsky P.
Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid. Pediatr Infect Dis J 1997;16:1060-1064.
16. Dean AG, Dean JA, Coulombier D. Epi Info, version 6: a word processing, database, and statistics program for public health on IBM-compatible microcomputers. Atlanta: Centers for Disease Control and Prevention, 1995.
17. Deeke SL, Palacio R, Ruvinsky R, et al. Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae. Pediatrics 1999;103:409-413.
18. del Castillo F, Baquero-Artigao F, Garcia-Perea A. Influence of recent antibiotic therapy on antimicrobial resistance of Streptococcus pneumoniae in children with acute otitis media in Spain. Pediatr Infect Dis J 1998;17:94-97.
19. Depardieu F, Courvalin P. Mutation in 23S RNA responsible for resistance to 16-membered macrolides and streptogramins in Streptococcus pneumoniae. Antimicrob Agents Chemother 2001;45:319-323.
20. Doern GV, Brueggemann AB, Huynh H, Wingert E. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997 98. Emerg Infect Dis 1999;5:757-765.
21. Dowell SF, Butler JC, Giebink GS. Acute otitis media: management and surveillance in an era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J 1999;18:1-9.
22. Dowell SF, Smith T, Leversedge K, Snitzer J. Failure of pneumonia treatment associated with highly resistant pneumococci in a child. Clin Infect Dis 1999;29:462-463.
23. Dunne WM Jr, Kehl KS, Holland-Staley CA, Brueggemann AB, Pfaller MA, Doern GV. Comparison of results generated by serotyping, pulsed-field restriction analysis, ribotyping, and repetitive-sequence PCR used to characterize penicillin-resistant pneumococci from the United States. J Clin Microbiol 2001;39:1791-1795.
24. Feikin DR, Schuchat A, Kolczak M. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000;90:223-229.
25. Heffelfinger JD, Dowell SF, Jorgensen JH. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000;160:1399-1408.
26. Hofmann J, Cetron MS, Farley MM, et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995;333:481-486.
27. Jacobs MR. Increasing importance of antibiotic-resistant Streptococcus pneumoniae in acute otitis media. Pediatr Infect Dis J 1996;15:940-943.
28. Tait-Kamradt A, Davies T, Appelbaum PC. Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob Agents Chemother 2000;44:3395-3401.
29. Thornsberry C, Ogilvie PT, Holley HP, Sahm DF. In vitro activity of grepafloxacin and 25 other antimicrobial agents against Streptococcus pneumoniae: correlation with penicillin resistance. Clin Ther 1998;20:1179-1190.
30. Turett GS, Blum S, Fazal BA, Justman JE, Telzak EE. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. Clin Infect Dis 1999;29:321-327.
31. Unge J, Berg A, Al-Kharadaghi S. The crystal structure of ribosomal protein L22 from Thermus thermophilus: insights into the mechanism of erythromycin resistance. Structure 1998;6:1577-1586.
Descargas
Cómo citar
1.
Muara Álvarez HD, Hernández Morgado JM, Villamil Fumero K. Generalidades de resistencia bacteriana en terapia intensiva. Mediciego [Internet]. 22 de septiembre de 2004 [citado 22 de diciembre de 2024];10(2). Disponible en: https://revmediciego.sld.cu/index.php/mediciego/article/view/2677
Número
Sección
Artículo de revisión
Licencia
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes de la Licencia CC Attribution-NonCommercial 4.0 International Deed (CC BY-NC 4.0):
Usted es libre de:
- Compartir — copiar y redistribuir el material en cualquier medio o formato
- Adaptar — remezclar, transformar y crear a partir del material
El licenciador no puede revocar estas libertades mientras cumpla con los términos de la licencia.
Bajo las condiciones siguientes:
- Atribución — Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.
- NoComercial — No puede utilizar el material para una finalidad comercial.
- No hay restricciones adicionales — No puede aplicar términos legales o medidas tecnológicas que legalmente restrinjan realizar aquello que la licencia permite.
La revista no se responsabiliza con las opiniones y conceptos emitidos en los trabajos, son de exclusiva responsabilidad de los autores. El Editor, con la asistencia del Comité de Editorial, se reserva el derecho de sugerir o solicitar modificaciones aconsejables o necesarias. Son aceptados para publicar trabajos científico originales, resultados de investigaciones de interés que no hayan sido publicados ni enviados a otra revista para ese mismo fin.
La mención de marcas comerciales de equipos, instrumentos o materiales específicos obedece a propósitos de identificación, no existiendo ningún compromiso promocional con relación a los mismos, ni por los autores ni por el editor.
